Liu Yaoyang, La Cava Antonio
Department of Medicine of the University of California Los Angeles, 1000 Veteran Avenue 32-59, Los Angeles, California 90095-1670, USA.
Recent Pat Inflamm Allergy Drug Discov. 2012 May;6(2):91-6. doi: 10.2174/187221312800166831.
Systemic lupus erythematosus (SLE) is a chronic disabling autoimmune disease that significantly impacts the quality of life of patients, and can associate with several complications including end-stage renal disease and shortened lifespan. A central component in the pathogenesis of SLE is the B-cell production of autoantibodies to multiple self-antigens. Since, B lymphocyte stimulator (BLyS) plays a key role in the selection, differentiation and survival of most B cells, it has been studied as a therapeutic target in SLE. After a gap of more than fifty years without new drugs being approved for this disease, the human neutralizing anti-BLyS monoclonal antibody belimumab has recently been approved by the FDA for SLE therapy. This review provides an overview on the targeting of BLyS in lupus animal models, the use of belimumab in human SLE, and relevant patents.
系统性红斑狼疮（SLE）是一种慢性致残性自身免疫性疾病，严重影响患者的生活质量，并可能伴有多种并发症，包括终末期肾病和缩短寿命。SLE发病机制的一个核心组成部分是B细胞产生针对多种自身抗原的自身抗体。由于B淋巴细胞刺激因子（BLyS）在大多数B细胞的选择、分化和存活中起关键作用，因此它已被作为SLE的治疗靶点进行研究。在五十多年没有新药获批用于该疾病之后，人源化抗BLyS单克隆抗体贝利尤单抗最近已被美国食品药品监督管理局（FDA）批准用于SLE治疗。本综述概述了在狼疮动物模型中针对BLyS的研究、贝利尤单抗在人类SLE中的应用以及相关专利。
